NCT07193680 NOPE37: Angiogenic Factors for Managing Term Preeclampsia
| NCT ID | NCT07193680 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Universitari Vall d'Hebron Research Institute |
| Condition | Preeclampsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 750 participants |
| Start Date | 2025-12-04 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 750 participants in total. It began in 2025-12-04 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study tests the hypothesis that, in women with preeclampsia without severe features, delivery management based on sFlt-1/PlGF would reduce the rate of induction of labor without worsening the rate of progression to preeclampsia with severe features and other maternal complications.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Singleton pregnancy * Preeclampsia without severe features according to the ACOG definition * Antegrade diastolic flow in the umbilical artery Doppler * Gestational age between 36+0 and 38+6 weeks of gestation * Gestational age confirmed by fetal crown-rump length measurement in the first-trimester scan (from 11+0 to 13+6 weeks of gestation) or by in vitro fertilization dates Exclusion Criteria: * Fetal death * Preeclampsia with severe features according to the ACOG definition, eclampsia, or any condition that requires immediate delivery * Absent or reversed end-diastolic flow in the umbilical artery Doppler * Non-reassuring CTG * Decreased fetal movements * Biophysical profile score ≤6 * Oligohydramnios * Refusal to provide informed consent * Fetal malformation * Placental abruption * Antiphospholipid antibody syndrome
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07193680 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Preeclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07193680 currently recruiting?
Yes, NCT07193680 is actively recruiting participants. Contact the research team at erika.bonacina@vallhebron.cat for enrollment information.
Where is the NCT07193680 trial being conducted?
This trial is being conducted at Barcelona, Spain, A Coruña, Spain, Alicante, Spain, Barcelona, Spain and 11 additional locations.
Who is sponsoring the NCT07193680 clinical trial?
NCT07193680 is sponsored by Hospital Universitari Vall d'Hebron Research Institute. The trial plans to enroll 750 participants.